K Hospital informs about 14 types of cancer that can be treated with Russian drugs

Russian medicine Pembroria is effective for lung, cervical, kidney cancer... but depending on each disease and each patient's case, the doctor will give a specific regimen.

K Hospital will soon introduce new drugs to treat cancer patients.

On November 13, K Hospital (Hanoi) provided more information about the Russian cancer treatment drug recently granted a circulation registration certificate by the Drug Administration of Vietnam - Ministry of Health . Pembroria contains the active ingredient pembrolizumab, 100mg/4ml vial manufactured by Limited Liability Company “PK-137”, Russian Federation. Pembroria is a biological drug with the same active ingredient as Keytruda, approved for the following indications:

Disease name	Disease name
1. Melanoma 2. Non-small cell lung carcinoma 3. Squamous cell carcinoma of the head and neck 4. Classic Hodgkin lymphoma 5. Urothelial carcinoma 6. Esophageal carcinoma 7. Cancers with high-grade microsatellite instability (MSI-H) or mismatch repair defects	8. Cervical cancer 9. Renal cell carcinoma 10. Endometrial carcinoma 11. Triple-negative breast cancer 12. Gastric adenocarcinoma 13. Gastroesophageal junction cancer 14. Cholangiocarcinoma.

The expected price of Pembroria is about 18 million VND/bottle, with the usual dose being 2 bottles for 1 treatment cycle. Thus, the cost for a patient's treatment cycle is about 36 million VND with a dose of 200mg (2 bottles). Currently, K Hospital has a plan to purchase Pembroria to use for patients in the near future.

However, according to the hospital representative, not everyone with the cancers listed above is prescribed drugs containing the active ingredient pembrolizumab. The use of pembrolizumab also depends on many factors such as: the patient's health status, the type of tumor mutation, the stage of the disease, etc.

At K Hospital, treatment is individualized for each patient. Based on a number of factors, the doctor will advise and provide a suitable treatment regimen to ensure effective treatment.

Pembrolizumab is the name of the active ingredient (active ingredient) invented by MSD (USA) with the trade name Keytruda, 100mg/4ml vial. Pembrolizumab is essentially a monoclonal antibody against PD-1 and is a biological drug indicated for certain types of cancer, belonging to the immunotherapy group. The drug is administered by intravenous infusion at a medical facility.

According to Vietnamnet

Source: https://baohaiphong.vn/benh-vien-k-thong-tin-ve-14-loai-ung-thu-co-the-dung-thuoc-dieu-tri-cua-nga-526606.html